Company intelligence / Profile preview
SixPeaks Bio AG
Basel, Basel-Stadt, Switzerlandsixpeaksbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Preclinical studies of the lead molecules show improved potency, biophysical properties, and pharmacokinetics/pharmacodynamics, as well as reduced off-target binding compared with competing antibodies. In both lean and obese mouse models, SixPeaks' lead molecules show potentially best-in-class efficacy for muscle mass preservation both as a single agent and when combined with GLP-1 agonists[2].
- Therapeutic areas
- Metabolic DisordersEndocrinologyCardiovascular
- Modalities
- AntibodiesmAb-peptide conjugatesbispecific antibodies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
AstraZeneca (strategic collaboration with option to acquire)
Beyond the preview
Go deeper on SixPeaks Bio AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SixPeaks Bio AG.